OT 2 0 2003 A

PECENED 1617

OCT 24 2003

TECH CENTED PATENT
0933 1615/25/

THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

SALONEN, Jukka T.

Conf.:

2024

Appl. No.:

10/014,590

Group:

1617

Filed:

December 14, 2001

Examiner: S. HUI

For:

METHOD FOR ASSESSING CARDIOVASCULAR

DISEASE

INFORMATION DISCLOSURE STATEMENT

(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 October 20, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a.

 This application was filed before June 30, 2003. Accordingly, submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. This application was filed on or after June 30, 2003. Accordingly, copies of cited U.S. patents and patent application publications therefore are not included. Copies of foreign patent documents and non-patent literature are included.
- c. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited

10/23/2003 RHEBRAHT 00000029 10014590

160.00 CP

01 FC:1806

in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

C. MENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

The following additional information is provided for the Examiner's consideration.

FEES

IV.		THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b): (check one box)						
	a.		within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.)					
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.					
	c.		concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.					
	d.		before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).					
V.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): ck one box)					
	C.F. mail	R. § ing d	e mailing date of a Final Office Action under 37 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the date of a Notice of Allowance under 37 C.F.R. See 37 C.F.R. § 1.97(c)(2)).					
	a.		No statement; therefore, a fee in the amount of \$\frac{180.00}{0}\$ as required by 37 C.F.R. § 1.17(p).					
	b.		See the statement below. No fee is required.					

VI.	STAT	EMENT	UNDER 37 C.F.R. § 1.97(e) (check only one box)							
	The	under	signed hereby states that							
	a.		each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or							
	b.		no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.							
	c.		Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.							
VII.	PAYMENT OF FEES (check one box)									
	\boxtimes	eck in the amount of $$180.00$ as required by 37 R. § 1.17(p) is enclosed for the above- cified fee.								
		amour above	se charge Deposit Account No. 02-2448 in the at required by 37 C.F.R. § 1.17(p) for the e-indicated fee. A triplicate copy of this paper stached.							
		No fe	ee is required.							

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Marchy, Jr., #28,977

MaryAnne Armstrong, Ph.D., #40,069

GMM/MAA:bmp 0933-0179P P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s): ⋈ PTO-1449

□ Documents

M Foreign Search Report

□ Other:

(Rev. 09/30/03)

Sheet

of

(10/20/03)

Form PTO-1449

INFORMATION SOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 0933-0179P APPLICATION NO. 10/014,590

APPLICANT

SALONEN, Jukka T.

FILING DATE

December 14

GROUP 11617

					December 14, 2001		1617		
			U	.S. PATENT I	OCUMENTS				
EXAMINER INITIAL	DOCU	MENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILIN IP APPE	G DATE ROPRIAT
	US	6,242,186	B1	2001-06-05	Salonen				
	τ	JS							
	Ţ	JS			-				
	τ	JS							
	US								
	τ	JS							
	τ	JS							
	US								
	Ţ	JS							
	Ţ	JS							
			FOR	EIGN PATENT	DOCUMENTS	***			
	Office			DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
		NUMBER			n am			YES	NO
	PCT	WO 01/04264	A2	2001-01-18	PCT				
	PCT	WO 00/56177	A2	2000-09-28	PCT				
	PCT	WO/00/55318	A2 ·	2000-09-21	PCT				
					title of the article (when app			l	L

James, Richard W. et al., Atherosclerosis, Vol. 139, pp. 77-82 (1998); BIOSIS, Accession No. PREV1993 96084318

Kumon, Y. et al., Scandinavian Journal of Immunology, Vol. 48, No. 4, pp. 419-424 (1998); BIOSIS Accession No. PREV1998 00509316 (Abstract only).

Dubravka, J. et al., Croatian Medical Journal, Vol. 42, No. 2, pp. 146-150 (2001); BIOSIS Accession No. PREV2001 00335955 (Abstract Only) .

Morena, M. et al., Nephrology Dialysis Transplantation, Vol. 15, No. 3, pp. 389-395; (2000); BIOSIS, Accession No. PREV2000 00158177 (Abstract only)

Senti, M. et al., Medline Accession No. 11231922 (Abstract only); Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 21, No. 3., pp. 415-420, (2001),

Salonen, J.T. et al., Scandinavian Journal of Social Medicine, Vol. 13, No. 3, pp. 99-102 (1985); BIOSIS Accession No. PREV1985 80099594 (Abstract only)

Perova, N. et al., Ann. Epidemol., Vol. 5, pp. 179-185 (1995)

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.